AACR 2025 – Merck's head and neck headscratcher
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
The same trial that sent Summit up 272% sees the stock crash 36%.
But sasanlimab's use looks set to remain narrow.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
AACR approaches, along with ASCO abstract titles.